SOMERSET, N.J. / May 29, 2024 / Business Wire / Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.
ABOUT LEGEND BIOTECH
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
| Last Trade: | US$31.48 |
| Daily Change: | 1.12 3.69 |
| Daily Volume: | 2,189,856 |
| Market Cap: | US$5.780B |
June 03, 2025 May 22, 2025 May 19, 2025 March 11, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
